Home > News > Foreword – US Ophthalmic Review, 2007,2:1
Macular Degeneration
Read Time: 2 mins

Foreword – US Ophthalmic Review, 2007,2:1

Published Online: February 23rd 2011 US Ophthalmic Review, 2007,2:1
Quick Links:
Article
Article Information
Article:

Ophthalmology is extremely well represented all over the world. However, in spite of dramatic technical improvements, blindness is still a major problem for millions of people. The International Council of Ophthalmology (ICO), with its 20/20 project, is trying hard to improve ophthalmic care, as well as improving the education of local doctors. Even sophisticated diagnostic and treatment modalities cannot yet eliminate severe visual impairment in several common diseases. Consequently, age-related macular degeneration (AMD) is still the first cause of severe visual impairment. It is not possible to prevent this disease with the use of anti-oxidating substances, as the point at which these treatments should be started is not known; theoretically, they should be used from childhood. New avenues for the treatment of AMD have been opened based on anti-angiogenetic substances; however, unfortunately they are not useful for atrophic forms and their side effects still need to be elucidated.

Glaucoma can be fought only by lowering intraocular pressure. Other forms of treatment, such as the use of neuroprotecting agents, require further validation. Diabetic retinopathy can be handled these days with enormous benefits for patients. Nevertheless, the efficacy of juvenile diabetes treatment, by prolonging the life expectancy of patients, has led to an increase in severe ophthalmic complications. Anterior segment surgery nowadays provides dramatic results with very low morbidity: in the case of cataract surgery, patients are practically able to drive home immediately after the procedure. This type of simplification— often encouraged by surgeons—should not detract attention from possible post-operative complications such as endoophthalmitis and retinal detachment. Luckily, the latter is extremely rare, but its immediate detection has an enormous impact on final functional results. The eye surface is an area in which fascinating new information has been collected, including on the role of tears. Amblyopia still affects 2% of the population. Its prevention or early treatment would be an excellent social investment, considering that today’s children have a life expectancy exeeding 80 years.

Ophthalmology is a mixed medico-surgical specialty. In recent years, the surgical aspect has been pushed forwards, both because of technological improvements and for budgetary reasons. Cataract and refractive surgery keep a large percentage of ophthalmologists busy. Retinal surgery requires higher investment in both personnel and equipment. Despite high costs, visual results are often questionable, particularly in macular pathologies. As a consequence, there are more and more gaps in education and practice in medical ophthalmology, for example in uveitis, neuro-ophthalmology, and eye involvement in systemic diseases. Even pediatric ophthalmology is having staffing difficulties; however, its strong links to strabismus surgery guarantee its survival.

In order to meet the needs of the people, ophthalmology ought to spend its energies in establishing guidelines not only for the appropriateness of diagnostic and surgical procedures, but also for providing standardized quantitative elements that would make the diagnosis and treatment of pathological conditions rational, useful, and economically acceptable. Today, the best ophthalmology can do is to aid prevention, early diagnosis, and appropriate treatment. It should tap into institutional and private sources in order to obtain financing for research devoted to the understanding of disease mechanisms. It is hoped that multidisciplinary research will elucidate the origin of eye diseases, with the dream of eliminating them for ever.

US Ophthalmic Review closely examines many of the issues and developments most salient in ophthalmology. I hope that it proves a valuable and informative read.

Article Information:
Received

2011-02-23

Further Resources

Share this Article
Related Content In Macular Degeneration
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72